Non-InvasiveInnovationsin Endometriosis Diagnostics and Staging

Endometriosis, affecting more than 10% of women globally (~ 200M+ women), is a debilitating inflammatory disorder caused by endometrial-like tissue implanting outside the uterus. It leads to severe pain, infertility, organ damage, internal scarring, and gastrointestinal issues, making it the number one cause of infertility.

With over 61 comorbidities, including cancers that impact mortality, endometriosis remains one of the largest diagnostic challenges in women’s health. Currently, diagnosis relies on histologic verification following laparoscopic surgery—the gold standard in the U.S.—but this invasive and costly method results in an average diagnostic delay of ~8 years, with ~36% of surgical diagnoses missed.

We prioritize precision, accessibility, and transformative care. By targeting endometrial tissue directly, we move beyond invasive surgery and the failures of liquid biomarkers, which promise convenience but thus far fail to provide meaningful results.

Our approach harnesses advanced molecular analysis of tissue collected via a simple, in-office procedure, analyzed with proprietary machine learning algorithms to evaluate gene expression data points. This ensures accuracy and reliability, providing clinicians and patients with actionable insights earlier than ever before.

We believe diagnostics should empower, not delay. By replacing invasive and reactive methods with precise, proactive solutions, we’re setting a new standard for women’s health diagnostics.

A paradigm shift in endometriosis care, the revolutionary diagnostic tool MetriDx™ replaces costly diagnostic laparoscopic surgery plagued by a calamitous 36% miss rate. MetriDx has the potential to redefine the spectrum of care. It offers clinicians the first reliable test to utilize when endometriosis is suspected, an opportunity they’ve not had before– ultimately, empowering them to create tailored treatment plans without relying on symptom-based guesswork.

MetriDx relies on the collection of a small sample of the endometrial tissue during a straightforward in-office procedure, and its analysis in a diagnostic lab via RT-PCR method. Proprietary machine learning algorithms process the gene expression data points to deliver robust results with a median sensitivity of 80%, and specificity of 95%.

Unlike liquid biopsy biomarkers, which may be suitable screening options, this approach relies on tissue where the disease originates from for a direct pathology-based diagnosis, positioning MetriDx as the only product that can substitute the canonical diagnostic laparoscopy. It rapidly brings unprecedented diagnostic capability to physicians, lowers liability risks for hospitals, and eliminates unnecessary surgical interventions while addressing significant diagnostic delays. 

Launching in 2026, this transformative tool sets a new standard in women’s health, delivering relief, earlier interventions, and life-changing outcomes.

Our diagnostic process embodies a commitment to precision, accessibility, and prioritizes patients. It starts with a simple in-office procedure, targeting the disease at its source.

This diagnostic workflow offers an end-to-end solution from the first doctor's visit to diagnosis. It relies on a RT-qPCR measurement of a messangerRNA biomarker list, allowing this test to be performed in any laboratory in the world, within a few days and at an affordable price.

More than a method, this process reflects a shift from reactive care to proactive solutions. Combining accessibility with scientific rigor, it transforms diagnostics into a tool of empowerment for clinicians and patients alike. Hera is taking diagnosis from decades to days.